SEC Form 4 filed by AIM ImmunoTech Inc.
$AIM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research Discussion highlights Ampligen's immune-modulating mechanism, prior Biosafety Level 4 findings and potential applicability across emerging viral threats New Ebola-focused corporate presentation highlighting Ampligen's antiviral research and preparedness potential is now accessible here Access the ‘What This Means' video segment here OCALA, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of a Virtual Investor "What This Means" video segment featuring AIM Chie
OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring disqualifying pre-treatment circumstances. The final planned subject is scheduled for treatment in mid-June, surpassing the Company's original enrollment target of July 2026 in the Phase 2 clinical trial of AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the "DURIPANC" stud
Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Investor "Ebola: What This Means" Segment on June 4th at 9:00 AM ET OCALA, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced it will release an on-demand video presentation detailing important previously published pre-clinical findings supporting the potential role of its lead drug Ampligen® (rin
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
Maxim Group resumed coverage of AIM ImmunoTech with a rating of Buy and set a new price target of $2.00
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an
Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Amo
Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, t
OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends ("Alternate Securities"). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the fourth quarter and full year 2024 and provided a business
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Execu
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)